D. E. Shaw & Co. Inc. Reduces Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE)

D. E. Shaw & Co. Inc. decreased its position in Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 54.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,536,633 shares of the biopharmaceutical company's stock after selling 1,841,017 shares during the quarter. D. E. Shaw & Co. Inc. owned approximately 1.35% of Fate Therapeutics worth $2,535,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Baker BROS. Advisors LP raised its holdings in Fate Therapeutics by 8.7% in the fourth quarter. Baker BROS. Advisors LP now owns 3,258,402 shares of the biopharmaceutical company's stock worth $5,376,000 after purchasing an additional 260,630 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in Fate Therapeutics by 10.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,898,377 shares of the biopharmaceutical company's stock worth $4,782,000 after purchasing an additional 279,360 shares in the last quarter. Walleye Capital LLC raised its holdings in Fate Therapeutics by 1,502.0% in the fourth quarter. Walleye Capital LLC now owns 1,083,092 shares of the biopharmaceutical company's stock worth $1,787,000 after purchasing an additional 1,015,483 shares in the last quarter. Cerity Partners LLC increased its holdings in shares of Fate Therapeutics by 4,953.6% during the fourth quarter. Cerity Partners LLC now owns 823,134 shares of the biopharmaceutical company's stock valued at $1,358,000 after acquiring an additional 806,846 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in shares of Fate Therapeutics during the fourth quarter valued at $846,000. Institutional investors own 97.54% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Wedbush restated a "neutral" rating and set a $5.00 price target on shares of Fate Therapeutics in a report on Thursday, March 6th. Barclays dropped their price target on shares of Fate Therapeutics from $10.00 to $2.00 and set an "overweight" rating on the stock in a report on Wednesday, May 14th. Wall Street Zen raised shares of Fate Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 15th. Stifel Nicolaus dropped their price objective on shares of Fate Therapeutics from $5.00 to $3.00 and set a "hold" rating on the stock in a report on Thursday, March 6th. Finally, Wells Fargo & Company lowered their price target on shares of Fate Therapeutics from $5.00 to $4.00 and set an "equal weight" rating on the stock in a report on Thursday, March 6th. Eight research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $4.14.

Fate Therapeutics Stock Performance

Shares of Fate Therapeutics stock traded down $0.04 on Friday, hitting $1.16. 788,583 shares of the company traded hands, compared to its average volume of 2,237,581. The stock has a market capitalization of $132.94 million, a P/E ratio of -0.70 and a beta of 2.32. Fate Therapeutics, Inc. has a 52 week low of $0.66 and a 52 week high of $5.92. The business has a 50-day simple moving average of $1.04 and a 200 day simple moving average of $1.45.

Fate Therapeutics (NASDAQ:FATE - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.07. Fate Therapeutics had a negative net margin of 1,325.43% and a negative return on equity of 45.88%. The company had revenue of $1.63 million for the quarter, compared to analysts' expectations of $1.18 million. Research analysts expect that Fate Therapeutics, Inc. will post -1.63 earnings per share for the current year.

About Fate Therapeutics

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.